PAR DRUGS AND CHEMICALS
|
PAR DRUGS AND CHEMICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 9.21 | 7.49 | 18.87 | 7.75 | 5.60 |
| CEPS(Rs) | 11.84 | 10.15 | 11.73 | 6.12 | 6.19 |
| DPS(Rs) | - | 1.25 | - | 2.50 | - |
| Book NAV/Share(Rs) | 57.90 | 48.66 | 84.87 | 66.02 | 64.79 |
| Tax Rate(%) | 24.84 | 27.47 | 21.15 | 20.48 | 23.72 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.81 | 19.16 | 23.18 | 14.86 | 15.49 |
| EBIT Margin(%) | 14.04 | 15.51 | 22.25 | 10.68 | 9.92 |
| Pre Tax Margin(%) | 13.92 | 14.97 | 21.32 | 9.43 | 6.21 |
| PAT Margin (%) | 10.46 | 10.86 | 16.81 | 7.50 | 4.74 |
| Cash Profit Margin (%) | 13.45 | 14.73 | 20.89 | 11.85 | 10.47 |
| Performance Ratios | |||||
| ROA(%) | 13.53 | 11.88 | 17.01 | 8.56 | 4.78 |
| ROE(%) | 17.29 | 16.44 | 25.02 | 13.68 | 11.35 |
| ROCE(%) | 23.20 | 21.85 | 28.68 | 15.56 | 12.41 |
| Asset Turnover(x) | 1.29 | 1.09 | 1.01 | 1.14 | 1.01 |
| Sales/Fixed Asset(x) | 1.70 | 1.51 | 1.26 | 1.11 | 0.94 |
| Working Capital/Sales(x) | 3.06 | 2.96 | 2.74 | 4.75 | 30.65 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.66 | 0.80 | 0.90 | 1.07 |
| Receivable days | 59.70 | 66.50 | 65.58 | 59.99 | 59.42 |
| Inventory Days | 17.00 | 16.58 | 15.63 | 20.71 | 28.81 |
| Payable days | 84.87 | 110.04 | 107.79 | 85.91 | 96.78 |
| Valuation Parameters | |||||
| PER(x) | 15.20 | 21.34 | 3.28 | 2.03 | - |
| PCE(x) | 11.83 | 15.73 | 5.28 | 2.57 | - |
| Price/Book(x) | 2.42 | 3.28 | 1.46 | 0.48 | - |
| Yield(%) | - | 0.78 | - | 7.94 | - |
| EV/Net Sales(x) | 1.57 | 2.40 | 1.04 | 0.32 | 0.35 |
| EV/Core EBITDA(x) | 8.13 | 10.97 | 3.91 | 1.89 | 1.93 |
| EV/EBIT(x) | 9.86 | 13.71 | 4.12 | 2.65 | 3.05 |
| EV/CE(x) | 1.69 | 2.29 | 0.83 | 0.30 | 0.31 |
| M Cap / Sales | 1.80 | 2.62 | 1.25 | 0.35 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 27.54 | 23.58 | 8.78 | 20.56 | 9.31 |
| Core EBITDA Growth(%) | 12.21 | 1.46 | 69.70 | 15.14 | 2.80 |
| EBIT Growth(%) | 15.62 | -14.39 | 126.48 | 29.14 | 6.59 |
| PAT Growth(%) | 23.02 | -20.65 | 143.68 | 89.76 | 64.83 |
| EPS Growth(%) | 23.02 | -60.33 | 143.68 | 38.19 | -0.66 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.16 | 0.15 | 0.40 |
| Current Ratio(x) | 3.53 | 2.93 | 2.58 | 2.23 | 1.14 |
| Quick Ratio(x) | 3.15 | 2.61 | 2.39 | 1.96 | 0.79 |
| Interest Cover(x) | 114.21 | 28.97 | 23.93 | 8.55 | 2.68 |
| Total Debt/Mcap(x) | - | - | 0.11 | 0.31 | - |
Compare Financial Ratios of peers of PAR DRUGS AND CHEMICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PAR DRUGS AND CHEMICALS | ₹329.9 Cr | -1% | 17.2% | 64.2% | Stock Analytics | |
| PIDILITE INDUSTRIES | ₹150,180.0 Cr | -2.3% | -1.5% | 22% | Stock Analytics | |
| SOLAR INDUSTRIES INDIA | ₹81,632.0 Cr | 2.1% | 2.3% | 135.4% | Stock Analytics | |
| SRF | ₹76,822.9 Cr | -1.7% | -1.1% | 0.6% | Stock Analytics | |
| GUJARAT FLUOROCHEMICALS | ₹40,217.7 Cr | 0.3% | 14.4% | 6.3% | Stock Analytics | |
| DEEPAK NITRITE | ₹34,945.9 Cr | 4.9% | 16.3% | 29% | Stock Analytics | |
PAR DRUGS AND CHEMICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PAR DRUGS AND CHEMICALS | -1% |
17.2% |
64.2% |
| SENSEX | 0.2% |
-0.2% |
20.9% |
You may also like the below Video Courses
